RPG Life Sciences Limited (RPGLIFE) — Announcement

1 Announcement Neutral 📄 PDF

📢 Key Event
RPG Life Sciences partners with Archerchem for Naprosyn ES launch

💡 Investor Takeaway
The partnership expands RPG Life Sciences' chronic therapy portfolio with a differentiated product targeting a specific patient segment.

RPG Life Sciences announced a partnership with Archerchem Healthcare to launch Naprosyn ES, a combination NSAID drug for pain management with gastro-protection, targeting unmet needs in elderly and gastro-sensitive patients across India.

2 Announcement Neutral 📄 PDF

📢 Key Event
RPG Life Sciences receives SEBI-mandated compliance certificate for dematerialization

💡 Investor Takeaway
This confirms regulatory compliance for shareholding records ahead of quarterly reporting.

RPG Life Sciences announced receipt of a SEBI-mandated compliance certificate from MUFG Intime India confirming dematerialization of securities for the quarter ended June 30, 2026, validating adherence to depositary regulations and shareholder registry updates.

📊 Stock Analysis — RPGLIFE ✨ Ask AI About This